NZ527391A - Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors - Google Patents

Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Info

Publication number
NZ527391A
NZ527391A NZ527391A NZ52739102A NZ527391A NZ 527391 A NZ527391 A NZ 527391A NZ 527391 A NZ527391 A NZ 527391A NZ 52739102 A NZ52739102 A NZ 52739102A NZ 527391 A NZ527391 A NZ 527391A
Authority
NZ
New Zealand
Prior art keywords
alkyl
alkanediyl
substituted
amino
het2
Prior art date
Application number
NZ527391A
Other languages
English (en)
Inventor
Dominique Louis Nest Surleraux
Piet Tom Bert Paul Wigerinck
Daniel Getman
Wim Gaston Verschueren
Sandrine Vendeville
Bethune Marie-Pierre De
Kerpel Jan Octaaf Antoon De
Samuel Leo Christiaan Moors
Kock Herman Augustinus De
Marieke Christiane Johan Voets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NZ527391A publication Critical patent/NZ527391A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ527391A 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors NZ527391A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
NZ527391A true NZ527391A (en) 2005-04-29

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527391A NZ527391A (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Country Status (30)

Country Link
US (1) US7659404B2 (enExample)
EP (1) EP1370543B1 (enExample)
JP (1) JP4530612B2 (enExample)
KR (1) KR100870184B1 (enExample)
CN (2) CN101230067B (enExample)
AP (1) AP1504A (enExample)
AT (1) ATE343567T1 (enExample)
AU (1) AU2002302363B2 (enExample)
BG (1) BG66301B1 (enExample)
BR (1) BR0207862A (enExample)
CA (1) CA2438304C (enExample)
CY (1) CY1108073T1 (enExample)
CZ (1) CZ304273B6 (enExample)
DE (1) DE60215623T2 (enExample)
DK (1) DK1370543T3 (enExample)
EA (1) EA006096B1 (enExample)
EE (1) EE05385B1 (enExample)
ES (1) ES2275866T3 (enExample)
HR (1) HRP20030735B1 (enExample)
HU (1) HU229224B1 (enExample)
IL (2) IL157171A0 (enExample)
MX (1) MXPA03007236A (enExample)
NO (1) NO326174B1 (enExample)
NZ (1) NZ527391A (enExample)
PL (1) PL213327B1 (enExample)
PT (1) PT1370543E (enExample)
SI (1) SI1370543T1 (enExample)
SK (1) SK287582B6 (enExample)
WO (1) WO2002083657A2 (enExample)
ZA (1) ZA200306086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073511A1 (en) 1999-05-28 2000-12-07 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1356082A2 (en) 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
ATE343567T1 (de) 2001-02-14 2006-11-15 Tibotec Pharm Ltd Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
US7109230B2 (en) 2002-01-07 2006-09-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
WO2004003223A2 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
JP4879484B2 (ja) * 2002-08-02 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド 広スペクトルの2−アミノ−ベンゾチアゾールスルホンアミドhivプロテアーゼ阻害剤
PL374948A1 (en) * 2002-08-02 2005-11-14 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
PL1670773T3 (pl) * 2003-09-30 2007-06-29 Tibotec Pharm Ltd Sposób wytwarzania sulfonamidów benzoksazolu i ich związków pośrednich
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
AU2005244121B2 (en) * 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
ES2331257T3 (es) 2005-02-25 2009-12-28 Tibotec Pharmaceuticals Sintesis de precursores de inhibidores de proteasas.
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
CN116354903B (zh) * 2021-12-28 2025-09-09 南京药石科技股份有限公司 一种6-苯并噻唑磺酰氯的制备方法
WO2024206093A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Hiv-1p rotease inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2093073T3 (es) 1990-03-09 1996-12-16 Milliken Res Corp Materiales organicos que tienen restos poli(oxialquilenos) enlazados por un grupo sulfonamido y su preparacion.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU680635C (en) * 1992-08-25 2007-05-17 G.D. Searle Llc Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
DK0721331T3 (da) 1993-10-01 2002-02-11 Astrazeneca Ab Fremgangsmåde
JP4014220B2 (ja) 1995-01-20 2007-11-28 ジー.ディー.サール アンド カンパニー ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター
US6140505A (en) * 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
DK0815124T3 (da) 1995-03-10 2003-03-17 Searle & Co Heterocyckliske carbonylaminosyre-hydroxyethylamino-sulfonamidinhibitorer af retrovirale proteaser
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
EP0861249A1 (en) * 1995-11-15 1998-09-02 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69726729T2 (de) 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
TR199900990T2 (xx) 1997-03-26 1999-10-21 Janssen Pharmaceutica N.V. Antifungal ve polimer ile kaplanm�� �ekirde�e haiz peletler.
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
ID25551A (id) * 1997-12-24 2000-10-12 Vertex Pharma Bahan baku obat penghambat protease aspartil
AU767728B2 (en) 1998-06-19 2003-11-20 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
ATE500823T1 (de) * 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Arzneimittel zur behandlung von hiv-infizierten säugetieren
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
ATE343567T1 (de) 2001-02-14 2006-11-15 Tibotec Pharm Ltd Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren

Also Published As

Publication number Publication date
EE200300381A (et) 2003-12-15
AU2002302363B2 (en) 2008-05-01
US20040116485A1 (en) 2004-06-17
KR20030077017A (ko) 2003-09-29
BR0207862A (pt) 2004-06-22
HUP0303257A2 (hu) 2004-01-28
CY1108073T1 (el) 2014-02-12
MXPA03007236A (es) 2003-12-04
HRP20030735B1 (en) 2012-02-29
SK11022003A3 (sk) 2004-07-07
BG108143A (en) 2004-07-30
WO2002083657A3 (en) 2003-02-13
CA2438304C (en) 2011-04-12
CN100369904C (zh) 2008-02-20
SK287582B6 (sk) 2011-03-04
HU229224B1 (en) 2013-09-30
EA200300891A1 (ru) 2004-02-26
EA006096B1 (ru) 2005-08-25
PT1370543E (pt) 2007-02-28
US7659404B2 (en) 2010-02-09
NO326174B1 (no) 2008-10-13
DE60215623T2 (de) 2007-08-30
DE60215623D1 (de) 2006-12-07
DK1370543T3 (da) 2007-02-19
CN1525962A (zh) 2004-09-01
EP1370543B1 (en) 2006-10-25
AP1504A (en) 2005-12-10
NO20033584D0 (no) 2003-08-13
ZA200306086B (en) 2005-01-26
BG66301B1 (bg) 2013-03-29
ES2275866T3 (es) 2007-06-16
CN101230067A (zh) 2008-07-30
NO20033584L (no) 2003-10-14
CZ304273B6 (cs) 2014-02-12
WO2002083657A2 (en) 2002-10-24
IL157171A0 (en) 2004-02-08
PL363778A1 (en) 2004-11-29
CZ20032415A3 (cs) 2004-04-14
IL157171A (en) 2012-10-31
JP4530612B2 (ja) 2010-08-25
HRP20030735A2 (en) 2005-08-31
SI1370543T1 (sl) 2007-04-30
HK1061233A1 (en) 2004-09-10
CN101230067B (zh) 2011-06-15
AP2003002856A0 (en) 2003-09-30
EE05385B1 (et) 2011-02-15
PL213327B1 (pl) 2013-02-28
EP1370543A2 (en) 2003-12-17
CA2438304A1 (en) 2002-10-24
KR100870184B1 (ko) 2008-11-24
ATE343567T1 (de) 2006-11-15
JP2004518767A (ja) 2004-06-24

Similar Documents

Publication Publication Date Title
NZ527391A (en) Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
ATE349417T1 (de) 5-aminolaevulinsäure-ester als mittel zur photosensibilisierung in der chemotherapie
MXPA03010258A (es) 2-amino-benzoxazol sulfonamidas, inhibidores de amplio espectro de la vih proteasa.
AR047744A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR059314A1 (es) Derivados de las benzamidas y heteroarenos
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
HRP20201089T1 (hr) Postupak sinteze inhibitora indolamin 2,3-dioksigenaze
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
HRP20191431T1 (hr) Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak
MXPA03009179A (es) 2-(amino sustituido)-benzoxazol sunfonamidas, inhibidores de amplio espectro de la vih proteasa.
MY135226A (en) Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
AR056191A1 (es) Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
MXPA04008926A (es) Inhibidores de entrada a moleculas pequenas.
MXPA05001792A (es) Oxindolsulfonamida sustituida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro.
MXPA04008929A (es) Benzimidazol sulfonamidas sustituidas como inhibidores de amplio espectro de la proteasa del vih.
TW200612946A (en) Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors
AR045117A1 (es) Imidazo-pirimidinas y triazolo-pirimidinas:ligandos del receptor de benzodiazepina
CO5180536A1 (es) Inhibidores de proteasas catepsina
TH76125A (th) ของผสมของ 1-ฟีนิล-1,5-ไดไฮโดร-ไพริโด[3,2-b]อินโดล-2-โอนชนิดถูกแทนที่และสารยับยั้ง hiv อื่นๆ
AR035866A1 (es) 2-(amino sustituido)-benzotiazol sulfonamidas inhibidoras de proteasa de hiv de amplio espectro, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la manufactura de medicamentos
TH102359A (th) ตัวยับยั้งซับสทิทิวเทดเบนซิมิแดโซลซัลโฟแนมีด hiv โปรตีเอส ที่มีฤทธิ์กว้าง

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 FEB 2022 BY CPA GLOBAL

Effective date: 20140903

EXPY Patent expired